← Back to Clinical Trials
Recruiting NCT07655388

NCT07655388 Wound Healing, Dressing Type, and Dressing Change Frequency in THA

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07655388
Status Recruiting
Phase
Sponsor Clinical Center of Vojvodina
Condition Wound Healing Time
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2026-07-01
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 95 Years
Study Type INTERVENTIONAL
Interventions
VACUTEX™ wound dressingOctenisept® wound care dressing

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2026-07-01 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Surgical wound complications following primary total hip arthroplasty remain a significant clinical challenge despite advances in wound care technologies. The optimal choice of dressing and frequency of dressing changes remain insufficiently investigated, particularly regarding their influence on wound healing and the wound microenvironment. This prospective, randomized, controlled clinical trial aims to evaluate the impact of dressing type and dressing change frequency on surgical wound healing in patients undergoing primary total hip arthroplasty. Ninety patients will be allocated into three treatment groups receiving either a capillary-action dressing system (VACUTEX™) or standard dressings with different dressing change intervals. The study will assess time to complete wound epithelialization, postoperative wound complications, pain intensity, wound temperature, exudate pH, length of hospital stay, and time to suture removal. In addition, the study will investigate the potential role of wound temperature and exudate pH as early indicators of impaired healing and postoperative complications.

Eligibility Criteria

Inclusion Criteria: * Patients scheduled for primary total hip arthroplasty (THA) * Age ≥ 65 years * Ability to provide informed consent * Patients with closed surgical incision suitable for standard postoperative wound care Exclusion Criteria: * Revision hip arthroplasty * Active infection at the time of surgery * Immunosuppressive therapy or severe immunodeficiency * Known allergy to dressing materials used in the study * Severe peripheral vascular disease affecting wound healing * Inability to comply with follow-up protocol

Contact & Investigator

Central Contact

Andrijana Ćorić, MScN

✉ 912007d23@mf.uns.ac.rs

📞 +381611810756

Principal Investigator

Andrijana Ćorić

PRINCIPAL INVESTIGATOR

Faculty of Mediicne, University of Novi Sad

Frequently Asked Questions

Who can join the NCT07655388 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 95 Years, studying Wound Healing Time. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07655388 currently recruiting?

Yes, NCT07655388 is actively recruiting participants. Contact the research team at 912007d23@mf.uns.ac.rs for enrollment information.

Where is the NCT07655388 trial being conducted?

This trial is being conducted at Novi Sad, Serbia.

Who is sponsoring the NCT07655388 clinical trial?

NCT07655388 is sponsored by Clinical Center of Vojvodina. The principal investigator is Andrijana Ćorić at Faculty of Mediicne, University of Novi Sad. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology